Surrey Heartlands

Joint Formulary & PAD

Naloxegol - Constipation

You are here : Home > Formulary Search > Naloxegol - Constipation

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Opioid-induced constipation. Only after other laxatives have been unsuccessful.

Documentation

NICE Technology Appraisal
NICE TA345 - Naloxegol for treating opioid-induced constipation
Policy Statement
Naloxegol for constipation - Policy statement APC 172-2015 Oct2015.pdf
Evidence Review
Naloxegol for treating opioid-induced constipation - Evidence review - Oct 2015

PAD Profile

ChemicalSubstance :
Naloxegol
Indication :
Constipation
Group Name :
Keywords :
Laxatives, opioid induced constipation,
Brand Names Include :
Moventig
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Constipation
Supporting Documents :
3

Other Indications

Below are listed other indications that Naloxegol is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Constipation.

Committee Recommendations (2)

03 Jul 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC have adopted the CKS principles for the management of constipation in adults.

Management | Constipation | CKS | NICE

The CKS guidance covers the management of constipation in adults (including pregnant women and those who are breastfeeding), for short-duration and chronic constipation, and faecal loading and/or impaction.

Refer to the formulary for Traffic Light status / place in therapy of locally agreed treatment options.

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

In June 2016, Naloxegol was agreed as a treatment option where there has been an inadequate response to other laxatives.

See policy statement and the locally agreed "Constipation in Adults Guidance for Primary Care" - below